Mustafa Asım GEDİKLİ

Dr. Mustafa Asım GEDİKLİ

https://orcid.org/0000-0002-3494-7935
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2025 in Journal of Biochemical and Molecular Toxicology
Verified
Journal Article
Open access
ZJZiad Joha
Ziad Joha
OKOğuzhan Kalkan
Oğuzhan Kalkan
FYFatih Yulak
Fatih Yulak
MEMustafa Ergül
Mustafa Ergül
MGMustafa Asım GEDİKLİ
Mustafa Asım GEDİKLİ
Proton pump inhibitors (PPIs), including esomeprazole, impact the acidic tumor microenvironment, potentially influencing cancer cell behavior. By examining the combined effects of esomeprazole and cisplatin on SNU‐1 gastric carcinoma cells, this study sought to elucidate the mechanisms through which esomeprazole enhances cisplatin's cytotoxicity, potentially allowing for effective treatment with reduced cisplatin dosages. SNU‐1 cells were treated with varying doses of esomeprazole and cisplatin, alone and in combination. Cell viability was assessed using the XTT assay. Oxidative stress (TAS/TOS), apoptosis (Annexin V, cleaved PARP), mitochondrial membrane potential, and DNA damage (8‐oxo‐dG, γH2AX, ATM) were evaluated using flow cytometry and ELISA. Statistical significance was determined by ANOVA. Esomeprazole alone showed no significant effect on SNU‐1 cell viability, oxidative stress (TAS/TOS), apoptosis, mitochondrial membrane potential, or DNA damage. Cisplatin, however, significantly reduced cell viability (IC50 = 3.024 µg/mL), increased oxidative stress (decreased TAS, increased TOS), diminished apoptosis (increased Annexin V binding and cleaved PARP levels), disrupted mitochondrial membrane potential, and caused significant DNA damage (increased H2AX and ATM phosphorylation, and elevated 8‐oxo‐dG) ( p < 0.001). Notably, the combination of esomeprazole and cisplatin synergistically enhanced cisplatin's effects. The combination resulted in a significantly greater reduction in cell viability (CI < 1), a further increase in oxidative stress, a higher level of apoptosis, amplified mitochondrial depolarization, and potentiated DNA damage compared to cisplatin alone ( p < 0.001). Esomeprazole potentiates cisplatin‐induced cytotoxicity in SNU‐1 gastric cancer cells by enhancing oxidative stress, apoptosis, mitochondrial dysfunction, and DNA damage. This suggests a potential therapeutic strategy to improve cisplatin efficacy and overcome resistance in gastric cancer.

14 April 2022 in Bagcilar Medical Bulletin
Verified
Journal Article
Open access
MGMustafa Asım GEDİKLİ
Mustafa Asım GEDİKLİ
BKBetül Sarı Kalın
Betül Sarı Kalın
AAAhmet Aktaş
Ahmet Aktaş

23 April 2021 in Adıyaman Üniversitesi Sağlık Bilimleri Dergisi
Verified
Journal Article
Open access
PDF file
AAAhmet Aktaş Aktaş
Ahmet Aktaş Aktaş
MGMustafa Asım GEDİKLİ
Mustafa Asım GEDİKLİ
ASAli Sahi̇n
Ali Sahi̇n
Aim: In this study, we aimed to show whether there is a relationship between FMF disease and cardiovascular risk by comparing Triglyceride/HDL-Cholesterol ratios between FMF patients and the control group.Materials and Methods: A total of 300 patients, including 150 Familial Mediterranean Fever (FMF) patients and 150 control groups aged 18-65, were included in our study. Triglyceride/HDL-Cholesterol ratios of the patients were compared.Results: Triglyceride/HDL-Cholesterol ratio was statistically significantly higher in the FMF group than the control group (p=0.026).Conclusion: In FMF patients, the Triglyceride/HDL-Cholesterol ratio can be used as an inexpensive, reproducible predictor in showing a cardiac risk.

7 March 2024 in Cumhuriyet Medical Journal
Verified
Journal Article
Open access
PDF file
ZKZekeriya Keskin
Zekeriya Keskin
MGMustafa Asım GEDİKLİ
Mustafa Asım GEDİKLİ
Objective: Warfarin is the most commonly used oral anticoagulant in the treatment and prophylaxis of thromboembolic diseases. In order to prevent thrombosis and to avoid hemorrhagic complications, the patient's International Normalized Ratio (INR) is kept within a certain range according to the indication and monitored at certain intervals. Our aim in our study is to determine the percentage of patients using warfarin for various indications reaching target INR values. Methods: Patients who used warfarin for various indications at our hospital's Internal Medicine outpatient clinic between May 2023 and November 2023 were included in our study, and their INR results were recorded by retrospectively scanning them. Results: A study group was formed with a total of 130 patients. Patients using warfarin due to metallic heart valve replacement, AF, PTE and CVD were evaluated separately according to the target INR value. The percentage of patients with metallic heart valve replacement reaching the target INR value of 2.5-3.5 was calculated as 38.5% (n: 27). The percentages of patients with AF, PTE and CVD reaching their target INR values of 2-3 were calculated as 40% (n:16), 54% (n:7), 70% (n:5), respectively. Considering the entire study group, the percentage of reaching the target INR was calculated as 42% (n: 55). Conclusion: As a result, warfarin not being within the therapeutic range causes serious morbidity and mortality. In our study, the percentage of patients reaching the target INR was found to be 42%. This percentage is very low, and in order to increase this rate, it is necessary to increase patient awareness, increase the frequency of follow-up of patients and develop more effective follow-up strategies.

19 March 2024 in Cumhuriyet Medical Journal
Verified
Journal Article
Open access
PDF file
MAMuhammed Faruk Aşkın
Muhammed Faruk Aşkın
ŞTŞeyma Taştemur
Şeyma Taştemur
MGMustafa Asım GEDİKLİ
Mustafa Asım GEDİKLİ
FCFerhan Candan
Ferhan Candan
YKYener Koc
Yener Koc
Objective: One of the vital problems after earthquakes that caused many deaths and injuries is crush syndrome due to traumatic muscle damage. The aim of this study was to determine the clinical course of patients with crush syndrome and identify factors that may be associated with crush syndrome. Methods: After the two earthquakes of 7.7 and 7.6 magnitude affecting 11 provinces with the epicentre in Kahramanmaraş on 6 February 2023, 319 patients over the age of 18 were admitted to our hospital between 6-14 February. 87 of 319 patients received inpatient follow-up and treatment. The age, gender, duration of stay in the rubble, province of residence, operation performed, duration of hospital stay, amount of fluid given in the first 24 hours, amount of urine output in the first 24 hours, body trauma sites, some laboratory parameters at the time of admission and during follow-up were retrospectively evaluated from the hospital records of all 43 patients diagnosed with crush syndrome among the inpatients between 6-28 February. Results: The age of the patients was 39±19.6 years, duration of stay under the cave-in(hours) 22.74±36.32, duration of hospitalization(days) 7.26±5.42, amount of fluid given in the first 24 hours(ml) 4954.18±3142, amount of urine output in the first 24 hours(ml) 2646.42±2262.65, admission creatinine(mg/dl) 1.59±2.25, admission creatine kinase(CK)(U/L) 11716.37±18520. 44.2% of the patients were female, 72.1% came from Kahramanmaraş province, 46.5% underwent surgical intervention, 67.4% had an admission CK above 1000 u/l, 14% received hemodialysis treatment and 51.2% had a duration of hospitalization longer than 21 days. The effect of other parameters on the duration of hospitalization and the time to reach the reference range of CK and correlation with laboratory parameters were analysed. Conclusion: As a result, it is thought that the parameters affecting the time to reach the CK reference range and the duration of hospitalization can be used to calculate and reduce the duration of hospitalization in prospective crush syndrome cases.

12 November 2025 in Bratislava Medical Journal
Verified
Journal Article
Closed access
PDF file
ZKZekeriya Keskin
Zekeriya Keskin
MÇMaksut Alper Çelik
Maksut Alper Çelik
RSRamazan Hilmi Sağlam
Ramazan Hilmi Sağlam
NHNada Haroun
Nada Haroun
IAİrFan Atik
İrFan Atik
MGMustafa Asım GEDİKLİ
Mustafa Asım GEDİKLİ